NCT03555422 2026-04-13
ENGOT-EN5
Karyopharm Therapeutics Inc
Phase 3 Completed
Clinical Trials
12 trialsNCT04562389 2026-04-09
SENTRY
Karyopharm Therapeutics Inc
Phase 3 Active not recruiting
NCT06158841 2026-03-13
CERVINO
AbbVie
Phase 3 Recruiting
NCT07138209 2026-02-27
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
Qilu Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT05611931 2026-02-02
XPORT-EC-042
Karyopharm Therapeutics Inc
Phase 3 Recruiting
NCT05675319 2026-01-05
AlloRelapseMM
Universitätsklinikum Hamburg-Eppendorf
Phase 3 Terminated
NCT05028348 2025-12-04
A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma
European Myeloma Network B.V.
Phase 3 Active not recruiting
NCT07011056 2025-09-19
A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 3 Recruiting
NCT05726110 2024-10-22
Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia
Shanxi Bethune Hospital
Phase 3 Recruiting
NCT06613035 2024-09-25
Twice-per-weekSelinexor, 2 Days Melphalan
Institute of Hematology & Blood Diseases Hospital, China
Phase 3 Not yet recruiting
NCT03110562 2024-08-21
BOSTON
Karyopharm Therapeutics Inc
Phase 3 Completed
NCT04534725 2023-08-24
C-SMART
Peter MacCallum Cancer Centre, Australia
Phase 3 Completed